
Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).

Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).

Patients with chronic obstructive pulmonary disease (COPD) and muscle loss phenotype (MLP) have an elevated risk of all-cause or COPD-related mortality.

EVIdeNCE study data, from real-world practice, confirm the efficacy and safety that ibrutinib previously demonstrated in clinical trials involving patients with CLL, according to the study authors.

Binod Dhakal, MD, associate professor, Medical College of Wisconsin, is lead investigator of the CARTITUDE-4 study, from which data were used by the FDA to approve ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 1 prior line of therapy.

Robert Zimmerman, MD, discussed the adverse side effects associated with glucagon-like peptide-1 (GLP1) and multi-agonist therapies, as well as explored the challenges in developing these interventions.

New data show that survival in patients living with postoperative colorectal cancer (CRC) could be predicted using a nomogram model.

New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.

The principal investigator of the study leading to approval said this new immunotherapy could be a "game changer" in bladder cancer.

Research indicated that worsened glycemic, blood pressure, and obesity control, as well as increased alcohol consumption, leveled lipid control, and persistent socioeconomic disparities may have contributed to the decelerated cardiovascular mortality decline in recent years.

At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.

To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.

The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have failed at least 4 prior lines of therapy.

Session speakers at the Academy of Managed Care Pharmacy (AMCP) 2024 annual conference share their favorite parts of the event and the key takeaways they will leave the conference with.

Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics.

Findings from a study with a limited sample size suggest that patching is both effective and does not impede development in children who patch for at least 120 minutes each day.

A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.

Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).

Significant improvements were seen in ventilation heterogeneity in patients with severe asthma after 12 months of bronchial thermoplasty.

A tumor board looked to studies in ovarian cancer for guidance on use of immunotherapy in a rare case of clear cell carcinoma of the cervix.

Moyle v United States centers on whether emergency medical law supersedes state abortion laws; Change Healthcare’s CEO will testify regarding the cyberattack’s impact; public health officials warn of potential threat as bird flu virus spreads in mammals.

Only 11 cases of adverse events (AEs) were reported over a 6-year time frame, the investigators found, following administration of chimeric antigen receptor T-cell therapy (CAR T).

The analysis also found the therapy has a manageable safety profile.

Non-Hispanic Black (NHB) patients with ovarian cancer (OC) receive lower-quality end of life (EOL) care compared to their non-Hispanic White (NHW) counterparts, according to a study.

In an interview during The American Journal of Managed Care®'s Institute for Value-Based Medicine® event, held with Sutter Health, Ryan Stice, PharmD, BCPS, explains the impact virtual population health teams can have on improving access to care for patients with cardiometabolic conditions.

Seeking more data on adjuvant alectinib in patients who have resectable ALK-positive non–small cell lung cancer (NSCLC), investigators compared outcomes vs chemotherapy.

The Center on Health Equity and Access provides the latest developments related to the progress, challenges and gaps in health care with new research, ongoing meetings, and expert insights.

The randomized trial found that reducing sitting time over a 6-month period was association with reduced systolic blood pressure (BP) among a group of older patients with obesity and high rates of hypertension.

Traditionally, low-risk patients with myeloproliferative neoplasms (MPNs) are not given medication, but new data challenge that thinking, said Raajit Rampal, MD, PhD, hematologic oncologist, associate attending physician, Memorial Sloan Kettering Cancer Center.

A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.

The findings suggest there are ongoing disparities between Black and White patients with hepatocellular carcinoma (HCC) in terms of both outcomes and health care resource utilization.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
